[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

98

1 you."
2 DR. BOLOGNESI: Well, Sam, I certainly
3 agree with that. And, in fact, much of that
4 information is being accumulated, at least in some of
5 the MAC studies that are going on right now.
6 There may be other opportunities about how
7 to use MHC antigens other than just immune responses
8 to candidate vaccines that are really enticing, but I
9 don't think this is the time.
10 CO-CHAIRMAN FAUCI: Mark?
11 MR. HARRINGTON: I think before this
12 committee can make its deliberations responsibly, it's
13 important that we hear about the current immediately
14 almost about to be underway seropositive vaccine
15 trials that are underway through the immune-based
16 therapies working group at the ACTG.
17 And so I'd like to ask either Dr.
18 Valentine or Dr. Hoth about the immunogens that are
19 going to be studied in ACTG 209, 214 and whether the
20 Duke synthetic peptide is going into a Phase I study
21 and when the time line is for completion of those
22 Phase I studies because I think we need to know that
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]